cancer

A melanoma vaccine built on mRNA technology is being highlighted in medical news. The approach, similar to the technology used in some Covid-19 vaccines, is being studied as a way to train the immune system to recognize and attack melanoma cancer cells. If proven effective in trials, it could add a new personalized immunotherapy option for patients with advanced skin cancer.

AstraZeneca has invested $2bn in US biotech firm Summit Therapeutics as part of a major cancer research collaboration. The FTSE 100 drugmaker agreed to buy 109,000 shares in the Nasdaq-listed company at $18.36 per share, funding a tie-up aimed at developing new cancer treatments.

Researchers report that cancer cells entering a 'proliferative pause' — a dormant, slow-dividing state — may expose a critical window during which brain metastasis could be prevented. The finding suggests that targeting cells during this quiescent phase, before they resume growth in the brain, could open new preventive strategies against one of the deadliest consequences of cancer spread.

Researchers led by Dr. Jona Kayser at MPZPM report that physical processes in dense cell populations strongly influence the best timing of treatment cycles, with implications for both cancer therapy and antibiotics. Treatment resistance remains one of the central challenges in medicine, and the findings suggest that timing could be adjusted based on how tightly cells pack together rather than on biology alone. The work points to new ways of scheduling therapies to delay or avoid resistance.

Research published in Nature reports that the p53 tumour suppressor protein maintains a balance between transcription and DNA replication, and that this balance prevents chromothripsis, a catastrophic form of chromosome shattering linked to cancer. The finding adds to understanding of how p53 suppresses tumours beyond its established roles in cell-cycle control and apoptosis, and highlights genome instability mechanisms relevant to cancer research.